Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
06/2005
06/21/2005US6909007 Steroidal pharmaceutical compounds
06/21/2005US6908987 Comprises nucleotide sequences coding peroxisome proliferator activator receptor protein (PCG) for modulating thermogenesis in adipocytes and treating obesity
06/21/2005US6908943 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
06/21/2005US6908930 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors
06/21/2005US6908927 Reduction physical cigarette smoking
06/21/2005US6908924 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
06/21/2005US6908917 Chromone derivatives as matrix metalloproteinase inhibitors
06/21/2005US6908909 Liquid oral compositions comprising a calcium compound and an acidulant
06/21/2005US6908614 Anti-aging/menopause symptoms relief using ganoderma lucidum spores
06/21/2005US6908611 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
06/21/2005CA2286299C Process for improving glucose metabolism, satiety, and nutrient absorption in companion animals
06/21/2005CA2250372C 6-phenylpyridyl-2-amine derivatives
06/21/2005CA2125579C Ulcer prevention treatment composition and method
06/16/2005WO2005054432A2 Gene transfer for regulating smooth muscle tone
06/16/2005WO2005054213A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
06/16/2005WO2005053620A1 Method of treating a patient’s teeth using fluoride releasing glass composition
06/16/2005WO2005037188A3 Therapeutic agent for periodontal disease
06/16/2005WO1991001624A8 Use of calcium antagonists for treating scars
06/16/2005US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
06/16/2005US20050131347 Apparatus for delivery of therapeutic and/or diagnostic agents
06/16/2005US20050131237 Indole derivatives
06/16/2005US20050131236 Central nervous ystem disorders; neurodegenerative disorders; muscle contraction; endocrine diseases
06/16/2005US20050131200 Biocompatability; polyphosphoester/polyphosphoramidate linkages; improved gene delivery into muscles; DNA vaccines
06/16/2005US20050131161 Process for removing bile salts from a patient and alkylated compositions therefor
06/16/2005US20050131047 cardiovascular disorders
06/16/2005US20050131043 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
06/16/2005US20050131035 Medicaments
06/16/2005US20050131032 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
06/16/2005US20050131024 Antiinflammatory agents; autoimmune diseases; anticancer agents
06/16/2005US20050131023 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
06/16/2005US20050131009 Urea substituted imidazoquinolines
06/16/2005US20050131005 4-azasteroid derivatives as androgen receptor modulators
06/16/2005US20050131003 Heterocyclic compounds
06/16/2005US20050131000 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
06/16/2005US20050130981 Compounds
06/16/2005US20050130965 Inhibitors of p38 kinase
06/16/2005US20050130964 e.g 8-oxa-1-thia-benzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester; rheumatoid arthritis
06/16/2005US20050130962 Seratonin receptor antagonist; central nervous system disorders; halo phenyl substituents
06/16/2005US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
06/16/2005US20050130903 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/16/2005US20050130902 Upregulate expression of a gene encoding an antioxidative anzyme, such as superoxide dismutase or catalase; neurodegenerative, cardiovascular, cerebral, disorders, trauma, injuries, burns, cancer
06/16/2005US20050130881 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
06/16/2005US20050130286 For diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders
06/16/2005US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening
06/16/2005US20050130127 Coronavirus-like particles comprising functionally deleted genomes
06/16/2005US20050129784 Use of a chemically stabilized chlorite solution for inhibiting an antigen-specific immune response
06/16/2005US20050129774 Mixture with surfactant and another drug; analgesics; antiinflammatory agents
06/16/2005US20050129736 Compositions and methods for treating or preventing diseases of body passageways
06/16/2005US20050129629 Lactobaccillus; reducing Streptococcus concentration; adjust mucin in mouth; anticarcies agents; oral disease
06/16/2005DE10331723A1 Kappa-Agonisten Kappa agonists
06/16/2005CA2546926A1 Compositions for the treatment of afflictions of the oral cavity and upper respiratory tract
06/15/2005EP1541673A1 Novel probiotics for pet food applications
06/15/2005EP1541672A1 Composition for promoting the proliferation of lactobacillus casei subsp. casei
06/15/2005EP1541580A1 Sulfotransferase inhibitors
06/15/2005EP1541574A1 Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient
06/15/2005EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative
06/15/2005EP1541571A1 Bicyclic unsaturated tertiary amine compound
06/15/2005EP1541563A1 Ccr4 antagonist and medicinal use thereof
06/15/2005EP1541174A1 Drug or cosmetic
06/15/2005EP1541172A1 Remedy for intestinal diseases and visceral pain
06/15/2005EP1541153A1 Hepatitis c virus inhibitor comprising alpha-glycosylceramide as the active ingredient
06/15/2005EP1541149A1 Phosphodiesterase inhibitor
06/15/2005EP1541141A1 Therapeutic agent for hepatic disease
06/15/2005EP1541135A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof
06/15/2005EP1539977A2 Tiacumicin production
06/15/2005EP1539942A2 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
06/15/2005EP1539933A2 Methods of organ regeneration
06/15/2005EP1539930A2 Multi-step method for the differentiation of insulin positive, glucose
06/15/2005EP1539927A1 Probiotic bacterium: lactobacillus fermentum
06/15/2005EP1539810A1 Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof
06/15/2005EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors
06/15/2005EP1539765A1 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
06/15/2005EP1539764A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
06/15/2005EP1539763A1 Azaindole kinase inhibitors
06/15/2005EP1539748A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
06/15/2005EP1539742A1 Indole derivatives useful as histamine h3 antagonists
06/15/2005EP1539741A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics
06/15/2005EP1539732A1 Novel compounds
06/15/2005EP1539729A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
06/15/2005EP1539707A1 Method and compounds for promoting healing and reducing inflammation
06/15/2005EP1539701A1 Caspase inhibitors and uses thereof
06/15/2005EP1539696A2 Process for preparing quinolin antibiotic intermediates
06/15/2005EP1539695A1 N-4-piperidinyl compounds as ccr5 modulators
06/15/2005EP1539694A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity
06/15/2005EP1539693A1 Cannabinoid receptor agonists
06/15/2005EP1539687A1 Substituted glycine derivatives for use as medicaments
06/15/2005EP1539683A2 Phenol derivatives and their use as rotamase inhibitors
06/15/2005EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539678A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands
06/15/2005EP1539674A1 Amino-propanol derivatives
06/15/2005EP1539664A1 Crystallization of polyol compositions, crystalline polyol composition product and use thereof
06/15/2005EP1539662A1 Cannabinoid receptor ligands
06/15/2005EP1539284A2 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
06/15/2005EP1539216A2 Labelled somatostatin analogs backbone cyclized through metal complexation
06/15/2005EP1539188A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
06/15/2005EP1539170A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
06/15/2005EP1539156A1 Liquid dosage forms of acid labile drugs
06/15/2005EP1539137A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
06/15/2005EP1539120A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea
06/15/2005EP1538908A2 Novel substituted benzimidazole dosage forms and method of using same
1 ... 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 ... 1258